ETCAMAH

This brand name is authorized in Austria, Estonia, Lithuania, Romania.

Active ingredients

The drug ETCAMAH contains one active pharmaceutical ingredient (API):

1	Camizestrant UNII JUP57A8EPZ - CAMIZESTRANT
	Camizestrant is an oral selective oestrogen receptor degrader (SERD) and oestrogen receptor (ER) antagonist. Camizestrant binds to the ligand binding domain of ERα, antagonising the activity of ERα encoded by both wild-type ESR1 and mutated ESR1, and inducing proteasome-dependent degradation of ERα, without agonising ERα.
	Read more about Camizestrant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ETCAMAH Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BA05		L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BA Anti-estrogens
Discover more medicines within L02BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3161090
LT	Valstybinė vaistų kontrolės tarnyba	1107909
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W72144001